Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, Wolden SL, Parham DM, Rodeberg DA, Kao SC, Womer RB. Weiss AR, et al. Among authors: anderson jr. J Clin Oncol. 2013 Sep 10;31(26):3226-32. doi: 10.1200/JCO.2012.44.6476. Epub 2013 Aug 12. J Clin Oncol. 2013. PMID: 23940218 Free PMC article.
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Breneman JC, et al. Among authors: anderson jr. J Clin Oncol. 2003 Jan 1;21(1):78-84. doi: 10.1200/JCO.2003.06.129. J Clin Oncol. 2003. PMID: 12506174
Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, Anderson JR, Crist WM, Link MP. Spunt SL, et al. Among authors: anderson jr. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6072-9. doi: 10.1158/1078-0432.CCR-04-0654. Clin Cancer Res. 2004. PMID: 15447992 Clinical Trial.
Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Burke M, Anderson JR, Kao SC, Rodeberg D, Qualman SJ, Wolden SL, Meyer WH, Breitfeld PP; Soft Tissue Sarcoma Committee of the Children's Oncology Group. Burke M, et al. Among authors: anderson jr. J Clin Oncol. 2007 Nov 1;25(31):4909-13. doi: 10.1200/JCO.2006.10.4257. J Clin Oncol. 2007. PMID: 17971587 Clinical Trial.
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Arndt CA, et al. Among authors: anderson jr. J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770373 Free PMC article. Clinical Trial.
Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.
La TH, Wolden SL, Rodeberg DA, Hawkins DS, Brown KL, Anderson JR, Donaldson SS. La TH, et al. Among authors: anderson jr. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1151-7. doi: 10.1016/j.ijrobp.2010.03.050. Epub 2010 Jun 11. Int J Radiat Oncol Biol Phys. 2011. PMID: 20542386 Free PMC article. Clinical Trial.
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, Anderson JR, Meyer WH, Hawkins DS. Mascarenhas L, et al. Among authors: anderson jr. J Clin Oncol. 2010 Oct 20;28(30):4658-63. doi: 10.1200/JCO.2010.29.7390. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837952 Free PMC article. Clinical Trial.
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Raney RB, et al. Among authors: anderson jr. J Clin Oncol. 2011 Apr 1;29(10):1312-8. doi: 10.1200/JCO.2010.30.4469. Epub 2011 Feb 28. J Clin Oncol. 2011. PMID: 21357783 Free PMC article. Clinical Trial.
2,109 results